321435-99-8

Basic information

• Product Name: 7-Bromo-2,3,4,5-tetrahydro-1H-benzo[b]azepine hydrochloride
• Synonyms: 7-Bromo-2,3,4,5-tetrahydro-1H-benzo[b]azepine hydrochloride;7-Bromo-2,3,4,5-tetrahydro-1H-benzo[b]azepine
• CAS NO: 321435-99-8
• Molecular Formula: C₁₀H₁₂BrN
• Molecular Weight: 262.57392
• Mol File: 321435-99-8.mol

Chemical Properties

• Boiling Point: 318.8±31.0 °C(Predicted)
• Appearance: /
• Density: 1.360±0.06 g/cm3(Predicted)
• PKA: 4.40±0.20(Predicted)
• CAS DataBase Reference: 7-Bromo-2,3,4,5-tetrahydro-1H-benzo[b]azepine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Bromo-2,3,4,5-tetrahydro-1H-benzo[b]azepine hydrochloride(321435-99-8)
• EPA Substance Registry System: 7-Bromo-2,3,4,5-tetrahydro-1H-benzo[b]azepine hydrochloride(321435-99-8)

Safety Data

• Hazardous Substances Data: 321435-99-8(Hazardous Substances Data)

Upstream product

• 4424-80-0 2,3,4,5-tetrahydro-1H-1-benzo[b]azepin-2-one 
• 1701-57-1 2,3,4,5-tetrahydro-1Hbenzo[b]azepine 
• 3470-53-9 6-amino-1-tetralone 
• 66361-68-0 (E)-6-bromo-3,4-dihydronaphthalen-1(2H)-one oxime 
• 66361-67-9 6-bromo-3,4-dihydro-2H-naphthalen-1-one 
• 137046-56-1 5-Brom-2<(4-ethoxy-1,4-dioxobutyl)amino>benzoesaeureethylester 
• 120572-43-2 diethyl ester of succinoylanthranilic acid 
• 87-25-2 2-ethoxycarbonylaniline 
• 201230-82-2 carbon monoxide 
• 267002-57-3 2-allyl-4-bromoaniline 
• 137046-58-3 7-bromo-3,4-dihydro-1H-1-benzazepine-2,5-dione 

Relevant articles and documents

Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model

Histone deacetylase 6 (HDAC6) is a promising therapeutic target for the treatment of neurodegenerative disorders. SW-100 (1a), a phenylhydroxamate-based HDAC6 inhibitor (HDAC6i) bearing a tetrahydroquinoline (THQ) capping group, is a highly potent and sel

FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1

The present invention relates to compounds of formula I wherein A1, A2 R4 and Q are as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

BIARYL-CONTAINING COMPOUNDS AS INVERSE AGONISTS OF ROR-GAMMA RECEPTORS

The present invention relates to biaryl-containing inverse agonists of ROR-gamma receptors. The invention also provides pharmaceutical compositions comprising these biaryl- containing inverse agonists, and methods of modulating ROR-gamma receptors using these inverse agonists. Also provided are methods of using biaryl-containing inverse agonists to treat ROR-gamma mediated diseases.

Ionic diamine rhodium complex catalyzed hydroaminomethylation of 2-allylanilines

Ionic diamine rhodium complexes catalyze the hydroaminomethylation of 2-allylanilines. The reaction involves initial hydroformylation followed by reductive amination, which provides direct access to 1,2,3,4- tetrahydroquinolines and 2,3,4,5-1H-1-benzazepi

LXR modulators

A compound of formula I wherein A, X, q, R1, R2a, R2b, R2c, R3a, and R3b are defined herein.

Design, structure-activity relationship, and pharmacokinetic profile of pyrazole-based indoline factor Xa inhibitors

A new series of pyrazole-based factor Xa inhibitors have been identified as part of our ongoing efforts to optimize previously reported clinical candidate razaxaban. Concern over the possible formation of primary aniline metabolites via amide hydrolysis led to the replacement of the primary amide linker between the pyrazole and phenyl moieties with secondary amides. This was accomplished by replacing the aniline with a variety of heterobicycles, of which indolines were the most potent. The indoline series demonstrated subnanomolar factor Xa binding Kis, modest to high selectivity versus other serine proteases, and good in vitro clotting activity. A small number of indoline fXa inhibitors were profiled in a dog pharmacokinetic model, one of which demonstrated pharmacokinetic parameters similar to that of clinical candidate razaxaban.

Nitrogen containing heterobicycles as factor Xa inhibitors

This invention relates generally to nitrogen containing heterobicycles of formulas A and B: which are inhibitors of trypsin-like serine protease enzymes, especially factor Xa, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.